Who Takes Ventavis?
Life with Ventavis: Actual patient profiles†
Ventavis has been used in over 16,000 patients worldwide, so you can be confident regarding its use for treatment of NYHA Class III & IV pulmonary arterial hypertension (PAH)*. Your doctor may prescribe Ventavis. Appropriate patients who may receive Ventavis include:
- Stable NYHA Class III patients whom physicians believe they can help improve more.
- Patients taking an oral endothelin antagonist. It's proven safe in combination.†
- Patients who desire an alternative to pumps and needles required with other prostacyclin therapies.
I.V. therapy not an option
“The shorter treatment times have given me more time [in my day].”
Christopher A., Missouri
- Diagnosed with Heritable PAH* (HPAH) NYHA Class III in 2007
- Sings in the church choir
- Enjoys walking, photography, and spending time with friends
PAH* associated with scleroderma (PAH-SSc)
Grace F., North Carolina
- Diagnosed with PAH-SSc NYHA Class III in 2002
- Integrates her Ventavis therapy into her work schedule
- Partner has active role as caregiver, helping with all aspects of therapy
“I appreciate the portability of Ventavis [therapy]. I never had to stop work.”
Proven safety in combination‡1
“My doctor said I'd be a good candidate. I feel like I'm getting better.”
Debbie B., California
- Diagnosed with Idiopathic PAH* (IPAH) NYHA Class III in 2000
- Very involved with patient support group for PAH
Stable NYHA Class III
Howard S., Florida
- Diagnosed with Idiopathic PAH* (IPAH) NYHA Class III in 2009
- Enjoys hobbies with his wife Lynn
“[With Ventavis 20 mcg/mL], the time element was reduced.”
The 20 mcg/mL concentration is intended for patients who are maintained at the 5-mcg dose and who have repeatedly experienced extended treatment times which could result in incomplete dosing. Ventavis 10 mcg/mL ampules are still available. Ventavis should be taken 6 to 9 times daily, at least 2 hours apart.1
†In the pivotal clinical study for Ventavis, patients were studied for 12 weeks.1 Individual results may vary.
‡In a small, randomized, double-blind, placebo-controlled study (the STEP trial), 34 patients treated with an endothelin receptor antagonist (125 mg BID for at least 16 weeks) tolerated the addition of inhaled iloprost (up to 5 mcg 6 to 9 times per day during waking hours).1